Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ALN-62643----[2] 62, 109
2ALN-CC5----[4] 11, 62, 66, 109
3ALXN1210----[7] 2, 11, 13, 50, 62, 66, 109
4Anti-C5 antibody----[4] 11, 14, 62, 109
5C5 inh MAb, SKY59, RO/CH7092230----[2] 62, 109
6CCX168----[5] 43, 44, 66, 109, 222
7Cemdisiran[1] Cemdisiran---[4] 11, 62, 66, 109
8COVERSIN[1] Nomacopan[1] D11473 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109
9CROVALIMAB[1] Crovalimab[1] D11696 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109
10ECULIZUMAB[1] Eculizumab[1] D03940 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 11, 13, 14, 61, 62, 109, 222
11Fc- and CDR-modified humanised monoclonal antibody against C5----[3] 11, 62, 109
12IgG2/4?----[1] 109
13Iptacopan[1] Iptacopan[1] D12251 [1] CFB 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[5] 61, 62, 66, 109, 222
14LNP023----[5] 61, 62, 66, 109, 222
15MASP-2 antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[3] 64, 66, 109
16NM8074----[2] 62, 109
17OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[1] 109
18OMS721----[3] 64, 66, 109
19OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109
20OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109
21OMS721 Drug Product 185 mg/mL----[1] 109
22RAVULIZUMAB[1] Ravulizumab[1] D11054 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 2, 11, 13, 50, 62, 66, 109
23RO7112689/F03-01----[2] 62, 109
24RO7112689/F03-10----[2] 62, 109
25RVA576----[3] 62, 109, 162
26RVA576 (COVERSIN)[1] Nomacopan[1] D11473 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109
27Solaris----[2] 62, 109
28SOLIRIS[1] Eculizumab[1] D03940 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 11, 13, 14, 61, 62, 109, 222
29SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)[1] Eculizumab[1] D03940 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[3] 13, 62, 109
30SOLIRIS 300 mg concentrado para solución para perfusión[1] Eculizumab[1] D03940 [1] C5 💬[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 109
31 LNP023 HYDROCHLORIDE SALT----[5] 61, 62, 66, 109, 222